IAM Article - Everyday Counts for European SPCs
25 May 2016
Michael writes about a decision of the European Court of Justice who ruled on the question of how the term of a supplementary protection certificate (SPC) should be calculated if the grant of the relevant marketing authorisation is notified to the marketing authorisation holder some time after it is granted.
The decision will be welcomed by the innovative pharmaceutical industry, as it provides additional days of protection for a significant proportion of SPCs in each EU member state. Although the term extension will typically be only one to four days, the financial benefit – particularly for ‘blockbuster’ drugs nearing the patent cliff – may be significant. To read the full article, please click here.
This artical first appeared in IAM Life Sciences 2016, a supplement to IAM, published by Globe Business Media Group - IP Division.